Anticoagulation after Iliofemoral Vein Stenting - Old Versus New
| Autor: | Neil Davies, Anja B Drebes |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Patient characteristics Iliac Vein Stent patency 01 natural sciences Blood Vessel Prosthesis Implantation 03 medical and health sciences Antithrombotic treatment Drug Discovery Antithrombotic Humans Medicine Thrombus Vein 030304 developmental biology Venous Thrombosis Pharmacology 0303 health sciences business.industry Endovascular Procedures Anticoagulants Femoral Vein medicine.disease Blood Vessel Prosthesis 0104 chemical sciences Surgery 010404 medicinal & biomolecular chemistry medicine.anatomical_structure Etiology Stents business Cohort study |
| Zdroj: | Current Pharmaceutical Design. 24:4525-4533 |
| ISSN: | 1381-6128 |
| DOI: | 10.2174/1381612825666181226151114 |
| Popis: | In recent years, there has been an increasing interest in endovascular iliofemoral vein stenting to prevent/ alleviate symptoms related to proximal venous outflow obstruction. Maintaining long-term stent patency is one of the main challenges, and risk factors for the development of re-thrombosis are not well understood. Published data on the safety and efficacy of the procedure predominantly come from cohort studies mainly focusing on mechanical aspects relating to stent placement and flow. Aetiology of thrombus formation and thrombotic tendencies of patients due to underlying medical conditions are not captured well or linked to clinical outcomes, and the impact of choice and length of antithrombotic therapy have not been specifically investigated. Here, we review different procedure-related factors and patient characteristics that might increase the risk of re-thrombosis and the utility of antithrombotic treatment options currently available. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|